Treatment with IPL344 was well tolerated Changes in the slope of decline in ALSFRS-R demonstrated 48% slower disease progression (p=0.028); and 64% slower progression when adjusted for disease stage and rate (p=0.034) Study suggests benefits ...
GUANGZHOU, China , Jan. 10, 2024 /PRNewswire/ -- Guangzhou Fermion Technology Co., Ltd. (Fermion), a clinical-stage AI-based drug discovery company that specializes in developing drugs for autoimmune diseases and pain, has announced today ...
- First clinical trial to evaluate the safety and efficacy of OBI-992 (a.k.a BSI-992), a novel antibody drug conjugate (ADC) targeting TROP2 - Dosing of first patient in the Phase 1/2 clinical trial expected in early 2024 NEWARK, Del. ...
SHENZHEN, China , Jan. 5, 2024 /PRNewswire/ -- On the morning of January 3, Kexing Biopharm signed an international commercialization cooperation agreement on Eribulin Mesylate Injection , securing exclusive commercialization licensing ...
- Interim results in MSS CRC suggest that SAFEbody precision masking technology enables a new standard for anti-CTLA-4 therapy at higher, more frequent and repeat doses by overcoming longtime safety-limited efficacy challenges with this ...
TAIPEI, Taiwan, Jan. 03, 2024 (GLOBE NEWSWIRE) -- OBI Pharma, a clinical stage oncology company (4174.TWO), today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for ...
NORCROSS, Ga. , Jan. 2, 2024 /PRNewswire/ -- Hi-Tech Pharmaceuticals, a leading manufacturer of cutting-edge dietary supplements and weight management supplements, is proud to announce the launch of its latest product, SLIMAGLUTIDE®. This ...
NORCROSS, Ga. , Dec. 28, 2023 /PRNewswire/ -- Hi-Tech Pharmaceuticals, a leading manufacturer of cutting-edge dietary supplements and weight management supplements, is proud to announce the launch of its latest product, SLIMAGLUTIDE®. ...
SHANGHAI , Dec. 26, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, ...
CBL-514 Phase 2 Study Results for local fat reduction demonstrated 85.7% and 76.2% of participants lost at least 150mL and 200mL of abdominal subcutaneous fat in the treated area after receiving CBL-514 treatment(s). NEW TAIPEI CITY , ...
Alectinib, a molecule developed by Genentech, Inc has been granted approval by the Food and Drug Administration on April 18, 2024, for the adjuvant treatment of patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer ...
The immunotherapy-boosting drug N-803, with the brand name Anktiva, was granted approval by the U.S. Food and Drug Administration (FDA) on April 22, 2024, based on the positive outcome of a clinical trial ...
Biopharmaceutical companies are once again competing in the development of innovative drugs for metabolic dysfunction-associated steatohepatitis (MASH), after a series of failures faced by drug manufacturers. The US FDA approval of ...
A study was presented by the Gardy Health system in Atlanta, Georgia, US, at the 73rd Annual Scientific Session of the American College of Cardiology. The study was conducted to evaluate the frequency of heart failure hospitalizations (HFH) in ...
Generic drugs and Branded drugs are essentially the same, as they both have the same active ingredient. Generic drugs can provide the same therapeutic advantages as branded drugs at a reduced cost, as they do not have to undergo extensive ...
Subscribe to our Free Newsletters!